Application of Tripterygium wilfordii polysaccharide in the preparation of drugs for preventing and treating cholestatic liver injury
Through the combined use of refined trilobaceous polysaccharide and ursodeoxycholic acid, the problems of limited efficacy and adverse reactions of existing cholestatic liver injury treatment drugs have been solved, significantly improving the anti-inflammatory and antioxidant capacity of the liver, and reducing the anti-inflammatory and antioxidant capacity of the liver. Cholestatic liver injury provides new treatment pathways and reduces adverse reactions.
Patent Information
- Application Number
- CN202411053498.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-08-02
AI Technical Summary
The existing drugs for cholestatic liver injury are limited in efficacy and are often accompanied by adverse reactions. The lack of effective treatment plans leads to severe physical and mental burdens in patients.
The refined trilobaceous polysaccharide was prepared by leaching, anion exchange column purification and molecular sieve column purification, and used in combination with ursodeoxycholic acid to improve the anti-inflammatory and anti-inflammatory of the liver. Antioxidant ability, reduces the accumulation of bile acids and promotes the transport of bile acids.
Trichophytic polysaccharide significantly improves the liver's anti-inflammatory and antioxidant ability, reduces cholestatic liver damage, reduces the synthesis and accumulation of bile acids, provides new treatment pathways, and significantly reduces adverse reactions when combined use The occurrence of
Smart Images

Figure CN118615315B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and particularly relates to the application of Tripterygium wilfordii polysaccharide in the preparation of a medicine for preventing and treating cholestatic liver injury. Background Art
[0002] The etiology of cholestatic liver injury (CLI) is complex, mainly manifested by bile acid metabolism disorder and excessive accumulation in the liver. If not effectively intervened, it can evolve into liver fibrosis and cirrhosis, and in severe cases, it can lead to liver failure or even death. At the same time, CLI is also a high-risk factor for liver cancer and cholangiocarcinoma. However, the main therapeutic drugs currently approved for CLI, such as UDCA (ursodeoxycholic acid) and obeticholic acid, have limited efficacy, and some patients show no response or intolerance. For example, ursodeoxycholic acid can cause gastrointestinal adverse reactions such as diarrhea; obeticholic acid often causes adverse reactions such as skin itching and abdominal pain. Western medicine treatment of CLI is mainly aimed at the cause and related complications. There is no specific therapeutic drug, and the accompanying symptoms such as systemic itching and expensive medical expenses have caused serious physical and mental burdens on patients. Therefore, the preparation of drugs that can effectively reduce CLI is of great clinical significance. Summary of the invention
[0003] The purpose of the present invention is to solve the deficiencies of the prior art and provide the use of Tripterygium wilfordii polysaccharide in the preparation of a drug for preventing and treating cholestatic liver injury, specifically adopting the following technical scheme:
[0004] The first aspect of the present invention provides the use of Tripterygium wilfordii polysaccharide in the preparation of a drug for preventing and treating cholestatic liver injury.
[0005] The polysaccharide of Tripterygium wilfordii can enhance the anti-inflammatory and anti-oxidative damage effects of the liver, reduce the accumulation of bile acid in blood circulation and liver tissue, promote the transport of bile acid, and reduce cholestatic liver damage. The present invention broadens the application scope of the polysaccharide of Tripterygium wilfordii and also provides a new approach for the prevention and treatment of cholestatic liver damage.
[0006] As a further preferred embodiment, the above-mentioned Tripterygium wilfordii polysaccharide is obtained by the following steps:
[0007] S1: crushing the medicinal material of Sanyeqing and then placing it in an ethanol aqueous solution to extract the residue, then extracting the residue with water to obtain an extract, concentrating it, separating the supernatant, removing free protein, adding a precipitant to precipitate polysaccharides, centrifuging, and drying to obtain crude Sanyeqing polysaccharide;
[0008] S2: The crude extracted Tripterygium wilfordii polysaccharide is purified by anion exchange chromatography column and molecular sieve chromatography column in sequence to finally obtain Tripterygium wilfordii polysaccharide.
[0009] More preferably, the volume percentage concentration of ethanol aqueous solution in the above-mentioned three-leaf green polysaccharide process is 90%; the extraction temperature is 75 ℃-85 ℃; the water extraction temperature is 95 ℃-100 ℃; DEAE52 cellulose is used as anion exchange chromatography column filler during anion exchange chromatography column purification. Superdex 200 gel is used as molecular sieve chromatography column filler during molecular sieve chromatography column purification. The uronic acid content in the three-leaf green polysaccharide prepared by the above preparation method is 26.46%. Compared with the existing preparation method, this preparation method adopts a two-step purification to obtain refined three-leaf green polysaccharide, which has the advantages of simple operation and high yield.
[0010] The second aspect of the present invention provides the use of the above-mentioned Tripterygium wilfordii polysaccharide and ursodeoxycholic acid in combination in the preparation of a drug for preventing and treating cholestatic liver injury.
[0011] As a further preferred embodiment, the usage ratio of ursodeoxycholic acid to Tripterygium wilfordii polysaccharide is 1:2.5-5.
[0012] The beneficial effects of the present invention are:
[0013] (1) The present invention proposes the use of Tripterygium wilfordii polysaccharide in the preparation of drugs for preventing and treating cholestatic liver injury, wherein Tripterygium wilfordii polysaccharide can enhance the anti-inflammatory and anti-oxidative damage effects of the liver, reduce the accumulation of bile acid in blood circulation and liver tissue, promote the transport of bile acid, and alleviate cholestatic liver injury. According to the data results of the embodiments of the present invention, Tripterygium wilfordii polysaccharide can increase the level of NRF2 in the nucleus of hepatocytes in in vivo and in vitro experiments, thereby improving the anti-inflammatory and anti-oxidative damage capabilities of cells. At the same time, it promotes the mRNA and protein expression levels of FXR, SHP, BSEP, and MRP2, reduces the mRNA and protein expression of CYP7A1, reduces the synthesis of bile acid, promotes the excretion of bile acid, and alleviates cholestatic liver injury.
[0014] (2) The present invention also provides the use of trifoliate green polysaccharide and ursodeoxycholic acid in combination in the preparation of a drug for preventing and treating cholestatic liver injury. The combination of trifoliate green polysaccharide and ursodeoxycholic acid can also play a synergistic role in alleviating cholestatic liver injury, and also provides an experimental basis for clinical combined drug use.
[0015] (3) The present invention broadens the application scope of Tripterygium wilfordii polysaccharide, provides a new approach for the prevention and treatment of cholestatic liver injury, enriches the theory of the pharmacodynamic mechanism of Tripterygium wilfordii, and contributes to the development and utilization of Tripterygium wilfordii polysaccharide, which will achieve good economic and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1The results show the effect of THP on serum biochemistry in rats with ANIT-induced cholestatic liver injury (mean ± SD, n=6). Compared with the normal control group, * indicates p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01; compared with the UDCA treatment group, Δ means p <0.05, ΔΔ indicates p <0.01(A is ALT, B is AST, C is TBIL, D is ALP, E is γ-GT, and F is TBA).
[0017] Figure 2 The figure shows the pathological effect of THP on the liver of rats with ANIT-induced cholestatic liver injury (HE staining, ×200). A is the HE staining of liver tissue sections, and B is the injury score diagram (mean ± SD, n=6). Compared with the normal control group, * indicates p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01; compared with the UDCA treatment group, Δ means p <0.05, ΔΔ indicates p <0.01.
[0018] Figure 3 The figure shows the effect of THP on the oxidative damage factors in the liver of rats with ANIT-induced cholestatic liver injury, A is GSH, B is SOD, (mean ± SD, n=6), where * indicates that compared with the normal control group p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01; compared with the UDCA treatment group, Δ means p <0.05, ΔΔ indicates p <0.01.
[0019] Figure 4 The results show the effect of THP on the mRNA levels of Nrf2, Fxr and their downstream genes (Shp, Cyp7a1, Bsep, Mrp2) in the liver of rats with ANIT-induced cholestasis (mean±SD, n=6). Compared with the normal control group, * indicates p<0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01; compared with the UDCA treatment group, Δ means p <0.05, ΔΔ indicates p <0.01.
[0020] Figure 5 The results show the effect of THP on the level of NRF2 nuclear protein in the liver of rats with ANIT-induced cholestasis, and on the expression of FXR and its downstream related proteins (SHP, CYP7A1, BSEP, MRP2) in the liver (mean±SD, n=6). Compared with the normal control group, * indicates p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01; compared with the UDCA treatment group, Δ means p <0.05, ΔΔ indicates p <0.01.
[0021] Figure 6 The results show the effects of different doses of THP combined with UDCA on serum biochemical parameters in rats with ANIT-induced cholestatic liver injury (mean ± SD, n=6). Compared with the normal control group, * indicates p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01; compared with the UDCA treatment group, Δ means p <0.05, ΔΔ indicates p <0.01(A is ALT, B is AST, C is TBIL, D is ALP, E is γ-GT, and F is TBA).
[0022] Figure 7 The results show the effects of different doses of THP combined with UDCA on liver oxidative damage factors in rats with ANIT-induced cholestatic liver injury. A is GSH, B is SOD, (mean ± SD, n=6), where * indicates that compared with the normal control group p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p<0.01; compared with the UDCA treatment group, Δ means p <0.05, ΔΔ indicates p <0.01.
[0023] Figure 8 The results show the effect of THP on the survival rate of rat primary hepatocytes at 24 and 48 hours (A), the effect of THP on the survival rate of rat primary hepatocytes injured by ANIT (B), and the effect on ALT (C), AST (D), and LDH (E), (mean±SD, n=6), where * indicates that compared with the normal control group p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01.
[0024] Fig. 9 The figure shows the effect of THP on oxidative damage factors of primary rat hepatocytes injured by ANIT, A is GSH, B is SOD, (mean±SD, n=6), where * indicates that compared with the normal control group p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01.
[0025] Fig.10 The results show the effects of THP on the mRNA levels of Nrf2, Fxr and their downstream genes (Shp, Cyp7a1, Bsep, Mrp2) in primary hepatocytes of rats injured by ANIT (mean ± SD, n=6). Compared with the normal control group, * indicates p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01.
[0026] Fig.11 The results show the effect of THP on the nuclear protein level of NRF2 in primary hepatocytes of rats injured by ANIT, and on the liver FXR and its downstream related proteins (SHP, CYP7A1, BSEP, MRP2), (mean±SD, n=6), where * indicates that compared with the normal control group p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicatesp <0.05, ## indicates p <0.01.
[0027] Fig.12 The results show the effect of THP on the survival rate of L02 cells at 24 and 48 hours (A), and the effect of gene silencing (siNrf2 or siFxr) on the survival rate of ANIT-injured cells (B) and LDH (C) after THP intervention (mean±SD, n=6). Compared with the normal control group, * indicates p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01; compared with the THP20 treatment group, Δ indicates p <0.05, ΔΔ indicates p <0.01.
[0028] Fig.13 The results show the effect of gene silencing (siNrf2 or siFxr) on GSH (A) and SOD (B) in L02 cells injured by THP (mean±SD, n=6). Compared with the normal control group, * indicates p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01; compared with the THP20 treatment group, Δ indicates p <0.05, ΔΔ indicates p <0.01.
[0029] Fig.14 The results show the effect of gene silencing (siNrf2 or siFxr) on the mRNA levels of Nrf2, Fxr, Shp, Cyp7a1, Bsep, and Mrp2 in L02 cells injured by THP (mean±SD, n=6). Compared with the normal control group, * indicates p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01; compared with the THP20 treatment group, Δ indicates p <0.05, ΔΔ indicates p <0.01.
[0030] Fig.15The results show the effects of gene silencing (siNrf2 or siFxr) on the levels of NRF2 nuclear protein (NRF2(N)), FXR, SHP, CYP7A1, BSEP, and MRP2 in L02 cells injured by THP (mean±SD, n=6). Compared with the normal control group, * indicates p <0.05,** indicates p <0.01; compared with the model (ANIT) group, # indicates p <0.05, ## indicates p <0.01; compared with the THP20 treatment group, Δ indicates p <0.05, ΔΔ indicates p <0.01. DETAILED DESCRIPTION
[0031] The following will be combined with the embodiments and drawings to clearly and completely describe the concept, specific structure and technical effects of the present invention, so as to fully understand the purpose, scheme and effect of the present invention. It should be noted that the embodiments and features in the embodiments of this application can be combined with each other without conflict.
[0032] The main instruments used in the embodiments of the present invention are an ultrapure water system (MILLI-Q Gradient A10), an electronic analytical balance (XP205), a negative 80 degrees Celsius refrigerator (907), a high-speed refrigerated desktop centrifuge (3K3O), a low-speed desktop centrifuge (TGL-18), a high-speed tissue grinder (KZ-II), an electric constant temperature water tank (DK-8B), a vortex mixer (MX-F), a multifunctional enzyme label detector (Victor Nivo), an automatic biochemical analyzer (Chemray 800, Chemray240), a high-performance liquid chromatograph (Waters Acquity UPLC), a chromatographic column (Acquity UPLC BEH C18, 2.1 mm×100 mm, 1.7 µm), a mass spectrometer (Qtrap 5500), a nucleic acid detector (Nanodrop One C), and My Gene L96+ gene thermal cycler, RT-qPCR instrument (MyiQ2), electrophoresis system, dehydrator (Donatello), embedding machine (JB-P5), pathology slicer (RM2016), freezing table (JB-L5), tissue spreader (KD-P), oven (DHG-9140A), upright optical microscope (BX43).
[0033] Example 1
[0034] The preparation of Tripterygium wilfordii polysaccharide specifically comprises the following steps:
[0035] 1. Crude Extraction of Tripterygium wilfordii Polysaccharides
[0036] 100g of dried Sanyeqing medicinal material (origin: Yushan County, Jiangxi Province) was taken, crushed, and extracted three times with 90% (v / v) ethanol aqueous solution (temperature: 80 ℃). The residue was placed in a ventilated place to dry at room temperature, and then extracted three times with 100 ℃ hot water, filtered, and the extracts were combined. The extracts were centrifuged at 4000 rpm for 5 min, and the supernatant was filtered and concentrated by reduced pressure rotary evaporation (Shanghai Huxi HR-21) at 70 ℃. After cooling, 90% (v / v) ethanol aqueous solution was added to a final concentration of 80% (v / v), 4 ℃ overnight, centrifuged, and the precipitate was freeze-dried to obtain crude Sanyeqing polysaccharide.
[0037] 2. Purification of crude extract of Tripterygium wilfordii polysaccharide and preparation of refined Tripterygium wilfordii polysaccharide
[0038] 2.1 Anion exchange chromatography column purification
[0039] DEAE52 cellulose was used as the filler of anion exchange chromatography column. A constant flow pump (Lange Constant Flow Pump Co., Ltd.) was used to determine the flow rate. Deionized water was passed through the column for 3 to 5 column volumes to reach equilibrium (linear flow rate 2 cm / min). An appropriate amount of deionized water solution of crude polysaccharide after dialysis was loaded (linear flow rate 0.3 cm / min), and gradient eluted with deionized water, 0.1 mol / L, 0.2 mol / L, 0.3 mol / L, 0.4 mol / L, 0.5 mol / L, and 0.6 mol / L NaCl solution (linear flow rate 1 cm / min). The eluted components were collected in a test tube using an automatic fraction collector. The eluted components were detected by sulfuric acid-phenol method, and the 0.4 mol / L NaCl eluted component was concentrated by vacuum rotary evaporation (temperature 70 ℃), dialyzed for desalination (retention pore size 3000 kD), and freeze-dried to obtain the preliminary purified trifoliate green polysaccharide.
[0040] 2.2 Molecular sieve (gel) column purification
[0041] Superdex 200 gel was used as the molecular sieve (gel) column filler. A constant flow pump was used to determine the flow rate. Deionized water was passed through the column for 3 to 5 column volumes to reach equilibrium (linear flow rate 0.3 cm / min). The deionized water solution (concentration 8.0 mg / mL, linear flow rate 0.3 cm / min) of the preliminary purified polysaccharide was loaded. To achieve a good separation effect, the loading volume each time was 5% to 10% of the column volume. Deionized water was used for elution (linear flow rate 0.3 cm / min), and the eluted components were collected in a test tube using an automatic fraction collector. The sugar content in the eluted components was detected by the sulfuric acid-phenol method, and the eluted components were freeze-dried to obtain refined trifoliate green polysaccharide.
[0042] The chemical components of the refined Tripterygium wilfordii polysaccharide were identified, and the identification results are as follows:
[0043] The sugar content of the refined polysaccharide of Tripterygium wilfordii was 88.54% by sulfuric acid-phenol method; the uronic acid content of the refined polysaccharide of Tripterygium wilfordii was 26.46% by sulfuric acid-carbazole method; the protein content of the refined polysaccharide of Tripterygium wilfordii was lower than the detection limit by Coomassie brilliant blue method. The monosaccharide composition of the refined polysaccharide of Tripterygium wilfordii was mainly rhamnose, arabinose, galactose, glucose, mannose and glucuronic acid.
[0044] Example 2
[0045] In vivo efficacy and pathway regulation of Tripterygium wilfordii polysaccharide in alleviating cholestatic liver injury
[0046] 1. Materials and Methods
[0047] 1.1 Experimental Materials
[0048] The experimental materials used in this example are shown in Tables 1 to 3.
[0049] Table 1 Main drugs and their solvents
[0050]
[0051] Table 2 Biochemical detection related kits
[0052]
[0053] Table 3 Antibodies to major proteins
[0054]
[0055] 1.2 Rats grouping and treatment
[0056] Healthy male Sprague Dawley (SD) rats, SPF grade, weighing 180 g-220 g, were provided by Slake Jingda Laboratory Animal (Hunan) Co., Ltd., license number SCXK (Xiang) 2019-0017. The rat-related experiments involved in this invention are in compliance with the relevant requirements of the Laboratory Animal Management Regulations and Animal Experiment Management, and the experiments have been approved and supervised by the Experimental Animal Committee of Nanchang University. The experimental animals were kept in separate cages, the bedding was changed every 3 days, and they were adaptively fed for 3 days. They had free access to water and food during the experiment. The temperature of the breeding environment was 22±2℃, the relative humidity was 60%, and there was a 12-hour light and 12-hour night cycle per day.
[0057] 1.2.1 Group I
[0058] Rats were randomly divided into groups (6 rats in each group): normal control group, THP300 group, model group, ursodeoxycholic acid (UDCA) treatment group, THP75 treatment group, THP150 treatment group, THP300 treatment group, and UDCA+THP300 treatment group. The intervention drug (or solvent) was gavaged once a day from day 1 to day 7, and the ANIT model injury (or solvent) was gavaged on day 5. Samples were collected under anesthesia 4 hours after administration on day 7, and the rats were killed under anesthesia. The dosing schedule is shown in Table 4. THP is the Tripterygium wilfordii polysaccharide prepared in Example 1; ANIT is α-naphthalene isothiocyanate; UDCA is ursodeoxycholic acid.
[0059] Table 4 Dosage regimen for rats
[0060]
[0061] The preparation process of the above-mentioned drugs for rat administration is as follows:
[0062] (1) Using water for injection as the solvent, ① weigh the refined Tripterygium wilfordii polysaccharide to prepare Tripterygium wilfordii polysaccharide solutions with concentrations of 7.5 mg / mL, 15 mg / mL, and 30 mg / mL, respectively; ② weigh UDCA to prepare 6 mg / mL UDCA intragastric solution; ③ prepare UDCA (6 mg / mL) + THP (30 mg / mL) intragastric solution and place in a 4°C refrigerator for use.
[0063] (2) ANIT solution: Take an appropriate amount of ANIT powder, weigh it accurately, put it in a ceramic mortar, add an appropriate amount of olive oil (solvent), stir evenly to make an ANIT solution with a concentration of 6 mg / mL, and place it in a 4°C refrigerator for use.
[0064] (3) Preparation of 2% sodium pentobarbital: Weigh 1 g of sodium pentobarbital and dissolve it in water for injection to 50 mL. Store at 4°C in the dark until ready for use.
[0065] The intragastric volume was 10 mL / kg.
[0066] 1.2.1 Group II
[0067] The rats were randomly divided into groups (6 rats in each group): normal control group, model group, UDCA treatment group, UDCA+THP75 treatment group, UDCA+THP150 treatment group, and UDCA+THP300 treatment group. The intervention drugs (containing solvent) were gavaged once a day from day 1 to day 7, and ANIT (containing solvent) was gavaged to model injury on day 5. Samples were collected under anesthesia 4 hours after administration on day 7, and the rats were killed under anesthesia. The dosing schedule is shown in Table 5. THP is the Tripterygium wilfordii polysaccharide prepared in Example 1; ANIT is α-naphthalene isothiocyanate; UDCA is ursodeoxycholic acid.
[0068] Table 5 Dosage regimen for rats
[0069]
[0070] The preparation process of the above-mentioned drugs for rat administration is as follows:
[0071] (1) Using water for injection as the solvent, weigh refined Tripterygium wilfordii polysaccharide and UDCA to prepare UDCA (6 mg / mL) intragastric solution, UDCA (6 mg / mL) + THP (7.5 mg / mL) intragastric solution, UDCA (6 mg / mL) + THP (15 mg / mL) intragastric solution and UDCA (6 mg / mL) + THP (30 mg / mL) intragastric solution, and place them in a 4°C refrigerator for use.
[0072] (2) ANIT solution: Take an appropriate amount of ANIT powder, weigh it accurately, put it in a ceramic mortar, add an appropriate amount of olive oil, stir evenly to make an ANIT solution with a concentration of 6 mg / mL, and place it in a 4°C refrigerator for use.
[0073] (3) Preparation of 2% sodium pentobarbital: Weigh 1 g of sodium pentobarbital and dissolve it in water for injection to 50 mL. Store at 4°C in the dark until ready for use.
[0074] The intragastric volume was 10 mL / kg.
[0075] 1.3 Collection of biological samples
[0076] 48 hours after modeling, the rats were anesthetized and blood was collected from the inferior vena cava. The blood samples were placed at 4°C for 2 hours, centrifuged at 3500 rpm for 5 minutes, and the upper serum was aspirated and stored in a -80°C refrigerator.
[0077] Under anesthesia, liver tissue was separated and collected. One part of the liver tissue was washed with 1× PBS solution, and then liver tissue blocks of appropriate size were cut out and placed in a tissue fixation bottle containing 4% paraformaldehyde fixative. After 24 hours, the liver tissue was paraffin-embedded; the other part was cut into small pieces, washed again with 1× PBS solution, and packaged in EP tubes without nuclease and stored in a -80℃ refrigerator.
[0078] 1.4 Serum and liver tissue biochemical indicators and HE case detection
[0079] The serum was taken out from the ultra-low temperature refrigerator, dissolved (the serum sample was clear and transparent), processed according to the procedures of the ALT, AST, ALP, TBIL, γ-GT and TBA kits, and tested in a fully automatic biochemical detector.
[0080] Accurately weigh the tissue sample, and place the tissue sample and pre-cooled extract (1× PBS solution) in a special EP tube of the tissue grinder at a ratio of 9 mL per gram of tissue. Add grinding beads and grind the tissue under low temperature conditions (60 Hz, grinding for 120 s). Centrifuge the ground EP tube at 12,000 rpm for 5 min at 4°C, take the supernatant and aliquot it and store it in a -20°C refrigerator for later use. Obtain liver tissue homogenate, and determine the content of GSH and SOD in liver tissue according to the instructions of the kit.
[0081] After the rat liver tissue was embedded in wax blocks, the sections were sliced for HE staining and pathological examination of the liver tissue was performed. The main steps of the HE staining experiment were as follows:
[0082] (1) Dewaxing and dehydrating: paraffin sections of rat liver tissue were taken, baked at 60°C for 30 min, and treated with gradient xylene and gradient ethanol to dewax.
[0083] (2) Staining: Use Harris hematoxylin to stain the cell nucleus for 2 min, and use 1% water-soluble eosin to stain the cytoplasm for 3 min;
[0084] (3) Dehydration and sealing: Dehydrate with gradient ethanol, n-butanol and xylene, air-dry, and seal with neutral resin;
[0085] (4) Image acquisition and analysis: Observe and analyze under an upright optical microscope.
[0086] 1.5 Liver RT-qPCR and western blot experiments
[0087] 1.5.1 Extraction and concentration determination of total RNA from tissues
[0088] (1) Weigh about 80 mg of liver tissue and place it in an EP tube dedicated to the tissue grinder. Add 3 pre-cooled zirconium oxide grinding beads to each tube and add 1 mL of cell lysis buffer (called TransZol Up in the kit). Fix it in the tissue grinder and set the instrument to a vibration frequency of 70 Hz for 120 s. After the homogenization is completed, take it out and place it at room temperature for 5 min.
[0089] (2) Add 0.2 mL of chloroform to the EP tube, vortex for 30 seconds, incubate at room temperature for 3 minutes, and centrifuge at 10,000 × g in a high-speed refrigerated centrifuge at 4°C for 15 minutes;
[0090] (3) Pipette the upper aqueous phase into an RNase-free centrifuge tube, add an equal volume of anhydrous ethanol, and mix by inverting repeatedly (gently).
[0091] (4) Add the liquid to the nucleic acid purification column and centrifuge at 12,000 × g for 1 min at room temperature. If the volume is too large, centrifuge in multiple steps.
[0092] (5) Add 0.5 mL of CB9 to the purification column, centrifuge at 12,000 × g at room temperature for 1 min, discard the flow-through, and repeat twice;
[0093] (6) Add 0.5 mL of WB9 to the purification column, centrifuge at 12,000 × g for 1 min at room temperature, discard the flow-through, and repeat twice;
[0094] (7) Centrifuge at 12,000 × g for 2 min at room temperature to completely remove residual liquid;
[0095] (8) Take 0.1 mL of nuclease-free water and add it to the purification column. After leaving it at room temperature for 1 min, centrifuge it at 12,000 × g for 1 min at room temperature. The eluate is the total RNA sample.
[0096] (9) Transfer it to a new nuclease-free EP tube, take 1 μL of total RNA and test the concentration and purity on a nucleic acid detector. Place the remaining total RNA sample on ice for later use.
[0097] 1.5.2 Reverse transcription
[0098] (1) Reverse transcription preparation:
[0099] The reverse transcription kit was thawed in advance in a 4°C refrigerator, and the corresponding volume of RNase-free water was added according to the concentration of each total RNA sample;
[0100] (2) De-genomic gDNA and reverse transcription synthesis:
[0101] According to the kit instructions, under RNase-free conditions, the corresponding reagents were mixed and placed in the gene amplification instrument for reaction. After the reaction was completed, the samples were taken out and stored in a -20°C refrigerator for later use.
[0102] 1.5.3 Real-time quantitative PCR (RT-qPCR)
[0103] (1) Primer sequences were designed and synthesized by BGI. The following are the relevant primer sequences (see Table 6)
[0104] Table 6 Primer sequences for RT-qPCR analysis (rat-derived genes)
[0105]
[0106] (2) RT-qPCR amplification detection:
[0107] The reaction system with a total volume of 20 μL was composed of the following: cDNA fragment (1 μL), forward primer sequence (10 μM, 0.4 μL), rear primer sequence (10 μM, 0.4 μL), TransStart® Tip Green qPCR Super Mix (10 μL), and RNase-free water (8.2 μL). Amplification detection was performed according to the following procedure: pre-denaturation at 95 °C, 20 s (1× cycle), denaturation at 95 °C, 10 s, annealing at 55 °C, 15 s (40× cycle), extension at 72 °C, 10 s, and dissolution at 55 °C, 30 s (81× cycle).
[0108] 1.5.4 Protein extraction, quantification and western blot experiment
[0109] (1) Extraction of total tissue protein:
[0110] a. Place about 80 mg of liver tissue in a grinder-specific protein extraction EP tube, add 3 pre-cooled steel grinding beads, and then add 1 mL of RIPA mixed lysis buffer (RIPA and PMSF mixed in a volume ratio of 100:1);
[0111] b. Place the EP tube in a high-speed tissue grinder and grind it (60 Hz, time 120 s). After grinding, take it out and let it stand for 30 min at 4°C (shake once every 5 min, each time for 30 s). Centrifuge it at 12000×g at 4°C for 15 min. The supernatant is the total tissue protein.
[0112] c. Take an appropriate amount for BCA protein quantification, transfer the rest to a new EP tube, add 6× buffer with one fifth volume of total protein, place on a 100°C heating plate to denature it, cool to room temperature, and store in a -20°C refrigerator.
[0113] (2) BCA protein quantification:
[0114] Take 5 μL of protein supernatant and operate according to the BCA kit method. Use a multifunctional microplate reader to measure the OD value at a wavelength of 562 nm in a 96-well plate to calculate the concentration of the protein sample to be tested.
[0115] Cytoplasmic and nuclear protein extraction and BCA protein quantification
[0116] a. Take liver tissue, cut it into small pieces and add them into the EP tube for grinding and homogenization, and mix the A solution and B solution in the cytoplasm protein extraction kit according to the volume ratio of 20:1;
[0117] b. Add PMSF (final concentration 1 mM) to a mixture of appropriate amounts of Solution A and Solution B to prepare a tissue homogenate solution. Add 200 μL of homogenate solution to every 60 mg of tissue and perform mechanical grinding and homogenization.
[0118] c. Take out the EP tube and place it in an ice bath for 15 min; centrifuge at 2000 g for 5 min at 4 °C, transfer the supernatant to a pre-cooled EP tube, and use the remaining precipitate to extract plasma protein.
[0119] d. Add 50 μL of PMSF-containing nuclear protein extraction reagent to the precipitate and vortex for 30 s to completely suspend and disperse the precipitate, then return to the ice bath for 30 min (vortex once every 5 min, 30 s each time);
[0120] e. Centrifuge at 12 000 g for 10 min at 4 °C, then transfer the supernatant to a newly pre-cooled EP tube, which is the tissue nuclear protein;
[0121] f. Take 5 μL of protein sample and determine the protein concentration. Add one-fifth of the volume of 6× buffer to the remaining nuclear protein solution, place it on a heating plate at 100°C to denature it, cool it to room temperature, and store it at -20°C.
[0122] 1.5.5 Western blot experiment
[0123] The basic steps are: gel preparation (prepare 8% separation gel and 5% concentration gel), protein loading and electrophoresis (prepare new 1× electrophoresis solution, add it to the electrophoresis tank, remove the comb, add protein solution to each well in turn, add protein pre-stained Marker to the wells on both sides, set the starting voltage to 75 V, and after the Marker ribbons are separated, set it to 120 V to continue electrophoresis), wet transfer (the current is set to 200 mA, and the membrane is transferred for 90 min), blocking (place the PVDF membrane in a newly prepared blocking solution (5% milk), block at room temperature for 2 h), incubate with primary antibody, incubate with secondary antibody, and develop.
[0124] 1.6 Statistics
[0125] The measurement data were expressed as mean ± SD, the differences among the groups were compared with analysis of variance, and the pairwise comparisons were performed with one-way ANOVA. p <0.05 was considered statistically significant, and “*” indicated that the difference was not statistically significant compared with the normal control group. p <0.05, "**" indicates compared with the normal control group p <0.01; “#” indicates comparison with the model group p <0.05, “##” indicates compared with the model group p<0.01; "Δ" means compared with the UDCA treatment group p <0.05, “ΔΔ” means compared with the UDCA treatment group p <0.01; statistics were performed using Graphpad Prism 9.0.
[0126] 2. In vivo experimental data results
[0127] Figure 1 The figure shows the effect of THP on serum biochemical parameters in rats with ANIT-induced cholestatic liver injury. Figure 1 It can be seen that (1) compared with the normal control group, oral administration of THP300 did not significantly affect the serum ALT, AST, TBIL, ALP, γ-GT and TBA of rats, indicating that this dose is safe for rats; (2) compared with the model (ANIT) group, THP can reduce serum related indicators in a dose-dependent manner, and the serum biochemical indicators of the THP150 and THP300 treatment groups decreased more significantly ( P <0.01), the results showed that THP150 and THP300 intervention could alleviate ANIT-induced liver damage in rats and reduce cholestasis symptoms; (3) compared with the UDCA treatment group, serum indicators (ALT, AST, TBIL, ALP, γ-GT and TBA) further decreased when THP300 was used in combination, indicating that the combined use could further alleviate the damage of ANIT to rat liver cells.
[0128] Figure 2 The figure shows the pathological effect of THP on the liver of rats with ANIT-induced cholestatic liver injury (HE staining, ×200). Figure 2 It can be seen that (1) compared with the normal control group, no significant changes were observed in the liver tissue of rats in the THP300 group, the liver plates were radial, and the structures of the portal area, hepatic lobules, and central veins were clear; (2) the liver tissue cells of rats in the model group lost their normal morphology, and obvious regional necrosis, hemorrhage, and a large amount of inflammatory infiltration in the portal area were observed; (3) THP can reduce liver tissue damage in a dose-dependent manner, and this anti-damage effect was significantly increased after the combination of THP300 with UDCA.
[0129] Figure 3 The figure shows the effect of THP on GSH and SOD in the liver of rats with ANIT-induced cholestatic liver injury. Figure 3 It can be seen that (1) compared with the normal control group, the levels of GSH and SOD in the liver tissue of rats in the THP300 group after oral administration had no statistically significant effect ( P>0.05); while the liver GSH and SOD of rats in the model group were significantly decreased; (2) Compared with the model group, THP could dose-dependently upregulate liver GSH and SOD, indicating that THP has an antioxidant protective effect on rat liver damage caused by ANIT; (3) Compared with the UDCA treatment group, GSH and SOD were significantly increased when THP300 was used in combination, indicating that the antioxidant effect can be further exerted after combined use.
[0130] Figure 4 The figure shows the effect of THP on the mRNA levels of Nrf2, Fxr and their downstream genes (Shp, Cyp7a1, Bsep, Mrp2) in the liver of rats with ANIT-induced cholestasis. Figure 4 It can be seen that (1) compared with the normal control group, the expression of Nrf2, Fxr, Shp, Bsep and Mrp2 mRNA in the liver of rats in the THP300 group alone was significantly increased ( P <0.05); (2) Compared with the normal control group, except for the increased expression of Nrf2 mRNA in the liver tissue of the rats in the model group, the expressions of other mRNAs such as Fxr, Shp, Bsep and Mrp2 were decreased ( P <0.05); (3) Compared with the model group, THP increased the mRNA expression of Nrf2, Fxr, Shp, Bsep and Mrp2 in the liver in a dose-dependent manner, while decreasing the mRNA expression of Cyp7a1; (4) Compared with the UDCA treatment group, the mRNA levels of Nrf2, Fxr, Shp, Bsep and Mrp2 in the liver of rats in the UDCA+THP300 combined treatment group were further upregulated ( P <0.01), while the expression of Cyp7a1 mRNA was further decreased ( P <0.05). The above results indicate that THP is involved in the regulation of the expression of genes related to bile acid homeostasis through the Nrf2 and Fxr pathways.
[0131] Figure 5 The figure shows the effect of THP on the level of NRF2 in the liver of rats with ANIT-induced cholestasis, and on the liver FXR and its downstream bile acid-related metabolic transporters. Figure 5 It can be seen that compared with the normal control group, THP300 can upregulate the protein expression of FXR, SHP, BSEP and MRP2 in rat liver; compared with the normal control group, the expression of NRF2 nuclear protein (NRF2 (N)) in the liver of rats in the model group was significantly increased ( P <0.05, while the protein expressions of FXR, SHP, BSEP, MRP2 and CYP7A1 were decreased ( P<0.05), indicating that under ANIT injury, the body down-regulated bile acid synthase CYP7A1, reduced the expression of the main bile acid uptake and efflux proteins, and activated the protective effect of the NRF2 pathway while being injured; under ANIT injury, THP can increase the nuclear accumulation of NRF2 in the liver in a dose-dependent manner ( P <0.05), increased the protein expression of FXR, SHP, BSEP, and MRP2, and decreased the expression of CYP7A1 protein. The results suggest that THP intervention can activate the NRF2 and FXR pathways, reduce CYP7A1 and reduce the source of bile acid, and promote the expression of BSEP and MRP2 proteins to promote bile acid transport metabolism and restore the flow of bile acid. In addition, when UDCA was combined with THP300, the NRF2 nuclear protein, FXR, SHP, BSEP, and MRP2 proteins in the liver of rats in the UDCA treatment group were significantly increased, while the expression of CYP7A1 protein was decreased ( P <0.05).
[0132] Figure 6 The results show the effects of different doses of THP combined with UDCA on serum biochemical parameters in rats with ANIT-induced cholestatic liver injury. Figure 6 It can be seen that compared with the UDCA treatment group, the combined use of THP can dose-dependently reduce rat serum ALT, AST, TBIL, ALP, γ-GT and TBA, among which the combined dose ratio of UDCA to THP was 1:2.5-5 (that is, the combined dose of THP was 150 mg / kg and 300 mg / kg), and the reduction was statistically significant.
[0133] Figure 7 The results show the effects of different doses of THP combined with UDCA on oxidative damage factors in the liver of rats with ANIT-induced cholestatic liver injury. Figure 7 It can be seen that compared with the UDCA treatment group, the combined use of THP can increase rat liver GSH and SOD in a dose-dependent manner. The increase was statistically significant when the combined dose ratio of UDCA to THP was 1:2.5-5 (that is, the combined dose of THP was 150 mg / kg and 300 mg / kg).
[0134] In addition, we observed that after THP (150 mg / kg and 300 mg / kg) was used in combination with UDCA, the diarrhea of rats was significantly improved compared with the UDCA treatment group, and the rats were in better condition. This may be because THP has a toxicity-reducing and synergistic effect on UDCA, reducing the incidence of adverse reactions of UDCA such as diarrhea.
[0135] Example 3
[0136] In vitro efficacy and pathway regulation experiments of Tripterygium wilfordii polysaccharide in alleviating cholestatic liver injury
[0137] 1. Materials and Methods
[0138] 1.1 Isolation, culture and identification of primary rat hepatocytes
[0139] Healthy male Sprague Dawley (SD) rats, SPF grade, weighing 160-180 g, were provided by Slake Jingda Laboratory Animal (Hunan) Co., Ltd., license number SCXK (Xiang) 2019-0017.
[0140] 1.2 Isolation and culture of primary rat hepatocytes
[0141] (1) Rats were placed in a clean environment and adapted for 7 days before surgery. They were weighed, anesthetized by intraperitoneal injection of 2% sodium pentobarbital, fixed on a clean operating table, disinfected, and subjected to laparotomy.
[0142] (2) The portal vein is cannulated and fixed, the inferior vena cava is cut, and the liver is perfused with the pre-perfusion solution until the surface of the liver turns yellow;
[0143] (3) Then, digestive fluid is perfused until turtle-back-shaped cracks appear in the subcapsular tissue of the liver.
[0144] (4) Remove the digested liver, carefully remove the capsule and fibrous components, and separate rat liver cells by repeated blowing with a pipette. Terminate the digestion with 4°C perfusion fluid, and pass through a 100-mesh sieve to obtain a rat liver cell suspension.
[0145] (5) Then centrifuge at 800 rpm for 5 min at 4°C to obtain cell pellets, which are further purified with 48% Percoll separation solution. Centrifuge at 500 rpm for 5 min, discard the damaged cells in the supernatant, collect the lower precipitated cells, add 48% Percoll separation solution, centrifuge at 500 rpm for 3 min, discard the upper layer of cells and Percoll solution, and add WME mixed culture medium. Perform cell counting and subsequent operations.
[0146] (6) The obtained rat primary hepatocytes were cultured in WME mixed medium at 37°C and 5% CO2. According to the experimental needs, the cells were seeded in rat tail gelatin-coated 96-well plates, 24-well plates, or 6-well plates at an appropriate cell density. The culture medium was changed every 4 hours, and then changed every 24 hours.
[0147] 1.3 Cytotoxicity assay
[0148] (1) Drug concentration gradient in rat primary hepatocyte CCK8 experiment
[0149] THP toxicity test: culture medium (100 μL) containing 2 μM, 5 μM, 10 μM, 20 μM, 40 μM, 60 μM, 80 μM, and 100 μM THP was added respectively;
[0150] ANIT toxicity test: culture medium (100 μL) containing 2 μM, 5 μM, 10 μM, 20 μM, 40 μM, 60 μM, and 80 μM ANIT was added respectively;
[0151] (2) Drug concentration gradient in L02 cell CCK8 experiment
[0152] THP toxicity test: culture medium (100 μL) containing 2 μM, 5 μM, 10 μM, 20 μM, 40 μM, 60 μM, 80 μM, and 100 μM THP was added respectively;
[0153] ANIT toxicity test: culture medium (100 μL) containing 2 μM, 5 μM, 10 μM, 20 μM, 40 μM, 60 μM, and 80 μM ANIT was added respectively;
[0154] (3) CCK8 experimental steps:
[0155] a. After the drug treatment, place the 96-well plate in an incubator at 37°C and 5% CO2 and continue routine culture for 24 h and 48 h;
[0156] b. Take out the cells at different times, discard the culture medium, wash the cells twice with 1× PBS solution, and add 100 uL culture medium and 10 μL CCK-8 solution;
[0157] c. Place the cells in a 37°C, 5% CO2 incubator in the dark for 2 h;
[0158] d. The absorbance (OD value) of each culture system at a wavelength of 450 nm was measured by a multifunctional microplate reader;
[0159] e. Draw the cell growth curve with the measurement time as the horizontal axis and the OD value as the vertical axis.
[0160] 1.4 Experimental grouping and treatment of primary rat hepatocytes
[0161] 1.4.1 Experimental grouping of rat primary hepatocytes
[0162] Rat primary hepatocytes were divided into (1) normal control group; (2) THP20 group; (3) model group; (4) THP5 treatment group; (5) THP10 treatment group; (6) THP20 treatment group.
[0163] 1.4.2 Treatment of primary rat hepatocytes
[0164] Rat primary hepatocytes were cultured at 1×10 5 The cells were inoculated in a 6-well plate at a density of 100 / mL and cultured in a 37°C, 5% CO2 incubator for 24 h. After the cells adhered to the wall, fresh serum-containing culture medium was replaced and the cells were treated according to the experimental groups, namely, the normal control group and the model group were added with equal proportion of solvent (0.1% dimethyl sulfoxide), the THP20 group was incubated with 20 uM THP, and the THP5 treatment group, THP10 treatment group and THP20 treatment group were incubated with 5 uM, 10 uM and 20 uM THP, respectively. After the above groups were incubated for 24 h, except for the normal control group and THP20 group, which were added with equal proportion of solvent (0.1% dimethyl sulfoxide), the other groups were added with ANIT 50uM and incubated for another 24 h. h later, the cell survival rate, supernatant ALT, AST, LDH values, cellular GSH and SOD were measured, or total RNA, total protein or nuclear protein were extracted, and the gene changes of Nrf2, Fxr, Shp, Bsep, Cyp7a1 and Mrp2 were measured. Five replicate wells were set up for each group.
[0165] 1.5 Experimental grouping and treatment of L02 cells
[0166] 1.5.1 L02 cell experimental grouping
[0167] L02 cells were divided into (1) normal control group; (2) THP20 group; (3) model group; (4) THP20 treatment group; (5) THP20 treatment group + SiNrf2; (6) THP20 treatment group + SiFxr.
[0168] 1.5.2 L02 cell treatment
[0169] L02 cells were cultured at 5×10 5 The cells were inoculated in 6-well plates at a density of 100 / mL. When the cell confluence reached about 80% in an incubator at 37°C and 5% CO2, the treatment drugs were added according to the experimental groups. After 24 h of culture, the cell activity was determined by CCK8 kit, the LDH in the supernatant of L02 cell culture medium was determined, the cell GSH and SOD values were determined, or the total RNA, total protein and nuclear protein of the cells were extracted, and the gene changes of Nrf2, Fxr, Shp, Bsep, Cyp7a1 and Mrp2 in L02 cells were determined. In the gene silencing group, siNrf2 or siFxr sequences were transfected into cells by transfection kit 24 h before administration. Five replicate wells were set for each group.
[0170] 1.6 Statistics
[0171] The measurement data were expressed as mean ± SD, the differences among the groups were compared with analysis of variance, and the pairwise comparisons were performed with one-way ANOVA. p <0.05 was considered statistically significant, and “*” indicated that the difference was not statistically significant compared with the normal control group. p <0.05, "**" indicates compared with the normal control group p <0.01; “#” indicates comparison with the model group p <0.05, “##” indicates compared with the model group p <0.01; "Δ" means compared with the THP20-treated group p <0.05, “Δ” means compared with the THP20 treatment group p <0.01; statistics were performed using Graphpad Prism 9.0.
[0172] 2. In vitro experimental results
[0173] Figure 8 The figure shows the effect of THP on the survival rate of rat primary hepatocytes at 24 h and 48 h. Figure 8 A), Effect of THP on the survival rate of primary hepatocytes in rats with ANIT injury ( Figure 8 B) and ALT ( Figure 8 C in), AST ( Figure 8 D in), LDH ( Figure 8 E) in the Figure 8 It can be seen that when THP was 40μg / mL or below, the 24 h and 48 h survival rates of cells were greater than 80%. Compared with the model group, THP could increase the cell survival rate in a dose-dependent manner and reduce the ALT, AST, and LDH values, indicating that THP could reduce the damage of ANIT to rat primary hepatocytes.
[0174] Fig. 9 The figure shows the effect of THP on oxidative damage factors of primary rat hepatocytes injured by ANIT. A is GSH, B is SOD, and Fig. 9 It can be seen that compared with the model group, THP can increase the cell GSH and SOD values in a dose-dependent manner, suggesting that THP may increase the cell's anti-ANIT damage effect by providing GSH and SOD.
[0175] Fig.10 The figure shows the effect of THP on the mRNA levels of Nrf2, Fxr and their downstream genes (Shp, Cyp7a1, Bsep, Mrp2) in primary hepatocytes of rats injured by ANIT. Fig.10It can be seen that compared with the model group, THP can dose-dependently increase the levels of cellular Nrf2, Fxr, Shp, Bsep, and Mrp2 mRNA, and reduce the level of Cyp7a1 mRNA, suggesting that THP may alleviate ANIT-induced cell damage by regulating Nrf2, Fxr, and bile acid synthesis and metabolism-related genes (Cyp7a1, Bsep, and Mrp2).
[0176] Fig.11 The figure shows the effect of THP on the nuclear protein level of NRF2 in primary hepatocytes of rats injured by ANIT, and on the liver FXR and its downstream related proteins (SHP, CYP7A1, BSEP, MRP2), and the Fig.11 It can be seen that compared with the model group, THP can dose-dependently increase the levels of cellular NRF2 nuclear protein, FXR, SHP, BSEP, and MRP2 total protein, and reduce the level of CYP7A1 total protein, suggesting that THP may alleviate ANIT-induced cell damage by regulating NRF2, FXR and bile acid synthesis and metabolism-related gene proteins (CYP7A1, BSEP, MRP2).
[0177] Fig.12 The figure shows the effect of THP on the survival rate of L02 cells at 24 and 48 hours ( Fig.12 A), Effect of gene silencing (siNrf2 or siFxr) on the survival rate of ANIT-injured cells treated with THP ( Fig.12 B) and LDH ( Fig.12 C) in the Fig.12 It can be seen that when THP was 40μg / mL or less, the 24h and 48h survival rates of cells were greater than 80%. Compared with the model group, the cell survival rate of the THP20 treatment group was increased, while the LDH value of the cell supernatant was reduced; compared with the THP20 treatment group, silencing cell Nrf2 or Fxr could significantly inhibit the cell survival rate. The LDH value of the cell supernatant was significantly increased, indicating that silencing cell Nrf2 or Fxr could weaken the protective effect of THP on cells.
[0178] Fig.13 The results show the effect of gene silencing (siNrf2 or siFxr) on GSH expression in L02 cells injured by THP ( Fig.13 A) and SOD ( Fig.13 B) in the above, and is affected by Fig.13It can be seen that compared with the model group, the cellular GSH and SOD in the THP20 treatment group were significantly increased; compared with the THP20 treatment group, silencing cellular Nrf2 or Fxr could significantly inhibit cellular GSH and SOD. This suggests that silencing cellular Nrf2 or Fxr can weaken the increase of THP on cellular GSH and SOD, thereby weakening the antioxidant damage of THP to cells.
[0179] Fig.14 The results show the effect of gene silencing (siNrf2 or siFxr) on the mRNA levels of Nrf2, Fxr, Shp, Cyp7a1, Bsep, and Mrp2 in L02 cells induced by ANIT. Fig.14 It can be seen that compared with the model group, the mRNA levels of Nrf2, Fxr, Shp, Bsep, and Mrp2 in the THP20 treatment group were significantly increased, while the mRNA level of Cyp7a1 was significantly decreased; compared with the THP20 treatment group, silencing of Nrf2 or Fxr in cells could significantly inhibit the above-mentioned change trends, indicating that silencing of Nrf2 or Fxr in cells could weaken the regulatory effect of THP on Nrf2, Fxr, Shp, Cyp7a1, Bsep, and Mrp2 mRNA in cells.
[0180] Fig.15 The results show the effect of gene silencing (siNrf2 or siFxr) on the levels of NRF2 nuclear protein (NRF2(N)), FXR, SHP, CYP7A1, BSEP, and MRP2 in L02 cells induced by THP. Fig.15 It can be seen that compared with the model group, the levels of cellular NRF2 (N), FXR, SHP, BSEP, and MRP2 proteins in the THP20 treatment group were significantly increased, while the level of CYP7A1 protein was significantly decreased; compared with the THP20 treatment group, silencing cellular Nrf2 or Fxr could significantly inhibit the above changes. This suggests that silencing cellular Nrf2 or Fxr can weaken the regulatory effect of THP on cellular NRF2 (N), FXR, SHP, CYP7A1, BSEP, and MRP2.
[0181] The above is only a preferred embodiment of the present invention. The present invention is not limited to the above implementation. As long as the technical effect of the present invention is achieved by the same means, it should belong to the protection scope of the present invention. Within the protection scope of the present invention, its technical scheme and / or implementation method can have various modifications and changes.
Claims
1. The use of Tripterygium wilfordii polysaccharide in the preparation of a drug for preventing and treating cholestatic liver injury, characterized in that: The trifoliate green polysaccharide is obtained by the following steps: S1: crushing the medicinal material of Sanyeqing and then placing it in an ethanol aqueous solution to extract the residue, then extracting the residue with water to obtain an extract, concentrating it, separating the supernatant, removing free protein, adding a precipitant to precipitate polysaccharides, centrifuging, and drying to obtain crude Sanyeqing polysaccharide; S2: The crude extracted Tripterygium wilfordii polysaccharide is purified by anion exchange chromatography column and molecular sieve chromatography column in sequence to finally obtain Tripterygium wilfordii polysaccharide.
2. The use according to claim 1, characterized in that: The volume percentage concentration of the ethanol aqueous solution is 90%.
3. The use according to claim 1, characterized in that: The extraction temperature is 75 ℃-85 ℃.
4. The use according to claim 1, characterized in that: The water extraction temperature is 95 ℃-100 ℃.
5. The use according to claim 1, characterized in that: DEAE52 cellulose was used as anion exchange chromatography column filler during anion exchange chromatography purification.
6. The use according to claim 1, characterized in that: Superdex 200 gel was used as the molecular sieve chromatography column filler during molecular sieve chromatography column purification.
7. The use according to any one of claims 1 to 6, characterized in that: The uronic acid content in the polysaccharide of Tripterygium wilfordii is 26.46%.
8. Use of trifoliate green polysaccharide and ursodeoxycholic acid in combination in the preparation of a drug for preventing and treating cholestatic liver injury, characterized in that: The trifoliate green polysaccharide is obtained by the following steps: S1: crushing the medicinal material of Sanyeqing and then placing it in an ethanol aqueous solution to extract the residue, then extracting the residue with water to obtain an extract, concentrating it, separating the supernatant, removing free protein, adding a precipitant to precipitate polysaccharides, centrifuging, and drying to obtain crude Sanyeqing polysaccharide; S2: The crude extracted Tripterygium wilfordii polysaccharide is purified by anion exchange chromatography column and molecular sieve chromatography column in sequence to finally obtain Tripterygium wilfordii polysaccharide.
9. The use according to claim 8, characterized in that: The dosage ratio of ursodeoxycholic acid to Tripterygium wilfordii polysaccharide is 1:2.5-5.
